Manfred Schmitt

Title: Manfred Schmitt: Innovator in Cancer Treatment Technologies

Introduction

Manfred Schmitt is a prominent inventor based in Munich, Germany. He has made significant contributions to the field of cancer treatment, particularly in the area of triple-negative breast cancer (TNBC). With a total of 15 patents to his name, Schmitt's work focuses on innovative methods for assessing treatment responses in patients.

Latest Patents

Among his latest patents, Schmitt has developed methods for assessing the treatment response of TNBC patients to neo-adjuvant chemotherapy by analyzing CpG methylation. This invention relates to predicting the efficacy of anthracycline-based neo-adjuvant chemotherapy in TNBC by determining epigenetic changes within the PITX2 gene. By detecting the methylation state of CpG sites in the genomic sequence of PITX2, healthcare providers can estimate the response or failure of individual breast cancer patients to neo-adjuvant therapy. Another notable patent involves markers for predicting the outcome of anthracycline treatment in patients with cell proliferative disorders. This method determines the expression level of genes such as PITX2, TFF1, and PLAU, and includes sequences, oligonucleotides, and antibodies that can be utilized within these methods.

Career Highlights

Throughout his career, Schmitt has worked with various companies, including Wilex AG. His innovative approaches have positioned him as a key figure in the development of cancer treatment technologies.

Collaborations

Some of his notable coworkers include Viktor Magdolen and Nadia Harbeck, who have collaborated with him on various projects related to cancer research and treatment.

Conclusion

Manfred Schmitt's contributions to cancer treatment through his innovative patents highlight his dedication to improving patient outcomes. His work continues to influence the field of oncology and offers hope for more effective treatment options for patients with challenging diagnoses.